CN106075574A - 一种修复关节软骨损伤的凝胶支架的制备方法 - Google Patents
一种修复关节软骨损伤的凝胶支架的制备方法 Download PDFInfo
- Publication number
- CN106075574A CN106075574A CN201610577602.2A CN201610577602A CN106075574A CN 106075574 A CN106075574 A CN 106075574A CN 201610577602 A CN201610577602 A CN 201610577602A CN 106075574 A CN106075574 A CN 106075574A
- Authority
- CN
- China
- Prior art keywords
- sodium
- articular cartilage
- gel
- prepare
- hyaluronate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001188 articular cartilage Anatomy 0.000 title claims abstract description 31
- 206010007710 Cartilage injury Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 47
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 17
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 16
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008367 deionised water Substances 0.000 claims abstract description 13
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- 230000006378 damage Effects 0.000 claims description 6
- 238000002242 deionisation method Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- -1 2,2-Dimethylaziridine hydrochloric acid Chemical compound 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 210000000845 cartilage Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 7
- 230000007547 defect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- FGRJGEWVJCCOJJ-UHFFFAOYSA-N 2,2-dimethylaziridine Chemical compound CC1(C)CN1 FGRJGEWVJCCOJJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010061762 Chondropathy Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种修复关节软骨损伤的凝胶支架的制备方法,包括以下步骤:S1:准备重量份为5‑8份的透明质酸钠和20‑25份的去离子水,将透明质酸钠和去离子水混合,在10‑15℃下反应11‑14h,制得透明质酸钠溶液;S2:准备重量份为6‑9份的PLGA纳米颗粒和4‑7份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在15‑20℃下反应10‑15min,然后加入偶氮二异丁脒盐酸盐,在20‑25℃下反应20‑30min,制得透明质酸钠凝胶复合物溶液;S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。本发明能够高效快速的制备复关节软骨损伤的凝胶支架,方法简单,使用方便,成本低。
Description
技术领域
本发明涉及药物和医疗器械技术领域,尤其涉及一种修复关节软骨损伤的凝胶支架的制备方法。
背景技术
随着我国进入老龄社会,膝关节软骨损伤病人越来越多;目前对于此类疾病尚无好的治疗方法;目前临床上常用的软骨下骨打孔,骨软骨移植以及自身软骨细胞移植只能部分缓解症状,不能达到重建软骨缺损的目的,使用此类方法得到的修复组织主要成分为I型胶原蛋白,与原有透明软骨的II型胶原蛋白相比在生物学特性上相差甚远。
在软骨缺损处再生修复组织,重建软骨缺损的基本原理为:募集自身或者引入外源性的干细胞、较原始细胞于软骨缺损处,并在相关生长因子等作用下分化为软骨组织;关节腔中有多种类型的间充质干细胞可以被招募到软骨缺损处进行损伤修复,如骨髓间充质干细胞、关节滑液中的滑膜间充质干细胞以及髌下脂肪垫来源的脂肪间充质干细胞等;体液以及血液等均有诱导间充质干细胞定向迁徙的能力,而软骨微环境中的各种因子具有诱导间充质干细胞向软骨细胞定向分化的能力;但是,由于自身体内诱导因子作用效能的局限性以及缺乏细胞生长的三维空间环境,因而,不能产生和原有软骨组织类似的修复组织,为了解决软骨再生这一难题,国内外医学界在过去几十年间进行了大量的探索和研究;如研究各种生长因子来促进间充质干细胞向软骨细胞分化;研究基因转染技术来获得成软骨能力更强的种子细胞;研究新型的组织工程支架在体外构建组织工程化软骨进而植入体内等;但是,这些方法都存在各种局限性:生长因子由于免疫原性不能体内使用,基因转染技术存在安全性和致瘤性问题,组织工程化软骨植入与原有组织很难整合等;因而,目前这些方法都没有很好的解决问题;近年来,在软骨缺损处植入能募集并诱导自身间充质干细胞向软骨细胞分化的三维支架是有光明前途的治疗方式;植入三维多孔支架尤其是植入能缓释药物的支架材料因能招募更多的间充质干细胞并增强诱导效能,因而治疗软骨再生带来了巨大的希望,具有广泛的社会经济意义。
目前,研究应用较多的支架材料多为PLGA、PGA、胶原蛋白、纤维蛋白等,这些支架材料特点为能诱导细胞产生大量的I型胶原蛋白,而非II型胶原蛋白,因而不利于间充质干细胞向软骨细胞分化;而在药物缓释支架的研究领域,用来被缓释的药物多为生长因子,此类药物价格昂贵,而且具有免疫原性,体内应用有带来动物源性疾病的风险;因而,寻找到合适形式的、能促进细胞分泌软骨细胞外基质的支架材料以及安全有效、可以体内使用的诱导药物是解决软骨再生问题的关键。
发明内容
基于背景技术存在的技术问题,本发明提出了一种修复关节软骨损伤的凝胶支架的制备方法。
本发明提出的一种修复关节软骨损伤的凝胶支架的制备方法,包括以下步骤:
S1:准备重量份为5-8份的透明质酸钠和20-25份的去离子水,将透明质酸钠和去离子水混合,在10-15℃下反应11-14h,制得透明质酸钠溶液;
S2:准备重量份为6-9份的PLGA纳米颗粒和4-7份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在15-20℃下反应10-15min,然后加入偶氮二异丁脒盐酸盐,在20-25℃下反应20-30min,制得透明质酸钠凝胶复合物溶液;
S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
优选地,所述S1中,准备重量份为6-7份的透明质酸钠和21-24份的去离子水,将透明质酸钠和去离子水混合,在11-14℃下反应12-13h,制得透明质酸钠溶液。
优选地,所述S2中,准备重量份为7-8份的PLGA纳米颗粒和5-6份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在16-19℃下反应11-14min,然后加入偶氮二异丁脒盐酸盐,在21-24℃下反应22-28min,制得透明质酸钠凝胶复合物溶液。
优选地,所述S3中,将透明质酸钠凝胶复合物溶液填充至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
本发明中,所述一种修复关节软骨损伤的凝胶支架的制备方法的注射用修饰透明质酸钠凝胶,为高效交联凝胶,交联剂用量少,具有增强的稳定性和内聚性,具有优异的流变学性能,塑形性好且易于注射,体内保留时间长,填充效果好,而且仍能保持生物相容性,本发明能够高效快速的制备复关节软骨损伤的凝胶支架,方法简单,使用方便,成本低。
附图说明
下面结合附图和具体实施方法对本发明做进一步详细的说明。
图1为本发明一种修复关节软骨损伤的凝胶支架的制备方法的结构示意图。
具体实施方式
下面结合具体实施例对本发明作进一步解说。
实施例一
本实施例提出了一种修复关节软骨损伤的凝胶支架的制备方法,包括以下步骤:
S1:准备重量份为5份的透明质酸钠和20份的去离子水,将透明质酸钠和去离子水混合,在10℃下反应11h,制得透明质酸钠溶液;
S2:准备重量份为6份的PLGA纳米颗粒和4份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在15℃下反应10min,然后加入偶氮二异丁脒盐酸盐,在20℃下反应20min,制得透明质酸钠凝胶复合物溶液;
S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
实施例二
本实施例提出了一种修复关节软骨损伤的凝胶支架的制备方法,包括以下步骤:
S1:准备重量份为6份的透明质酸钠和23份的去离子水,将透明质酸钠和去离子水混合,在13℃下反应12h,制得透明质酸钠溶液;
S2:准备重量份为7份的PLGA纳米颗粒和5份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在18℃下反应13min,然后加入偶氮二异丁脒盐酸盐,在23℃下反应25min,制得透明质酸钠凝胶复合物溶液;
S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
实施例三
本实施例提出了一种修复关节软骨损伤的凝胶支架的制备方法,包括以下步骤:
S1:准备重量份为8份的透明质酸钠和25份的去离子水,将透明质酸钠和去离子水混合,在15℃下反应14h,制得透明质酸钠溶液;
S2:准备重量份为9份的PLGA纳米颗粒和7份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在20℃下反应15min,然后加入偶氮二异丁脒盐酸盐,在25℃下反应30min,制得透明质酸钠凝胶复合物溶液;
S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (4)
1.一种修复关节软骨损伤的凝胶支架的制备方法,其特征在于,包括以下步骤:
S1:准备重量份为5-8份的透明质酸钠和20-25份的去离子水,将透明质酸钠和去离子水混合,在10-15℃下反应11-14h,制得透明质酸钠溶液;
S2:准备重量份为6-9份的PLGA纳米颗粒和4-7份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在15-20℃下反应10-15min,然后加入偶氮二异丁脒盐酸盐,在20-25℃下反应20-30min,制得透明质酸钠凝胶复合物溶液;
S3:将透明质酸钠凝胶复合物溶液注入至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
2.根据权利要求1所述的一种修复关节软骨损伤的凝胶支架的制备方法,其特征在于,所述S1中,准备重量份为6-7份的透明质酸钠和21-24份的去离子水,将透明质酸钠和去离子水混合,在11-14℃下反应12-13h,制得透明质酸钠溶液。
3.根据权利要求1所述的一种修复关节软骨损伤的凝胶支架的制备方法,其特征在于,所述S2中,准备重量份为7-8份的PLGA纳米颗粒和5-6份的偶氮二异丁脒盐酸盐,将PLGA纳米颗粒加入透明质酸钠溶液中,在16-19℃下反应11-14min,然后加入偶氮二异丁脒盐酸盐,在21-24℃下反应22-28min,制得透明质酸钠凝胶复合物溶液。
4.根据权利要求1所述的一种修复关节软骨损伤的凝胶支架的制备方法,其特征在于,所述S3中,将透明质酸钠凝胶复合物溶液填充至待修复关节软骨损伤处,然后经紫外点光源照射,得到修复关节软骨损伤的凝胶支架。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610577602.2A CN106075574A (zh) | 2016-07-21 | 2016-07-21 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610577602.2A CN106075574A (zh) | 2016-07-21 | 2016-07-21 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106075574A true CN106075574A (zh) | 2016-11-09 |
Family
ID=57448775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610577602.2A Withdrawn CN106075574A (zh) | 2016-07-21 | 2016-07-21 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075574A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196342A1 (en) * | 2005-12-14 | 2007-08-23 | Sadozai Khalid K | Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects |
US20070202084A1 (en) * | 2005-12-14 | 2007-08-30 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
CN102727424A (zh) * | 2012-07-13 | 2012-10-17 | 常州药物研究所有限公司 | 用于骨关节腔的透明质酸钠凝胶针剂及其制备方法 |
CN104225677A (zh) * | 2013-06-13 | 2014-12-24 | 山东省生物药物研究院 | 交联透明质酸细胞支架材料及其制备方法和应用 |
CN104587531A (zh) * | 2014-12-25 | 2015-05-06 | 南京臻泉医药科技有限公司 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
-
2016
- 2016-07-21 CN CN201610577602.2A patent/CN106075574A/zh not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196342A1 (en) * | 2005-12-14 | 2007-08-23 | Sadozai Khalid K | Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects |
US20070202084A1 (en) * | 2005-12-14 | 2007-08-30 | Anika Therapeutics, Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
CN102727424A (zh) * | 2012-07-13 | 2012-10-17 | 常州药物研究所有限公司 | 用于骨关节腔的透明质酸钠凝胶针剂及其制备方法 |
CN104225677A (zh) * | 2013-06-13 | 2014-12-24 | 山东省生物药物研究院 | 交联透明质酸细胞支架材料及其制备方法和应用 |
CN104587531A (zh) * | 2014-12-25 | 2015-05-06 | 南京臻泉医药科技有限公司 | 一种修复关节软骨损伤的凝胶支架的制备方法 |
Non-Patent Citations (4)
Title |
---|
任杰等: "《氟复合材料应用技术》", 31 January 1997, 科学技术文献出版社 * |
张瀚文: "油田用丙烯酰胺类聚合物的研究发展", 《化工管理》 * |
赵亚奇等: "《高分子自由基合成技术研究》", 31 December 2017, 中央民族大学出版社 * |
金国珍等: "《工程塑料》", 31 January 2001, 化学工业出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Tough hydrogel with enhanced tissue integration and in situ forming capability for osteochondral defect repair | |
Huang et al. | A functional biphasic biomaterial homing mesenchymal stem cells for in vivo cartilage regeneration | |
Zhao et al. | Biomimetic composite scaffolds to manipulate stem cells for aiding rheumatoid arthritis management | |
KR101422689B1 (ko) | 콜라겐, 히알루론산 유도체 및 포유류의 탯줄 유래 줄기세포를 포함하는 연골세포치료제 | |
CN102470190B (zh) | 适用于治疗骨关节炎、韧带损伤和关节失调的生物材料 | |
CN103356694B (zh) | 治疗关节炎病症的长效药剂 | |
CN103785065B (zh) | 一种软骨再生支架材料的制备方法 | |
CN111068116B (zh) | 一种注射用软骨修复温敏凝胶及其制备方法 | |
US9889086B2 (en) | Bioadhesive and injectable hydrogel | |
Zhao et al. | Osteogenic growth peptide accelerates bone healing during distraction osteogenesis in rabbit tibia | |
CN108404204A (zh) | 丝素蛋白水凝胶 | |
Zerbinati et al. | A new hyaluronic acid polymer in the augmentation and restoration of labia majora | |
Zhao et al. | Recent developments and current applications of hydrogels in osteoarthritis | |
CN102416201A (zh) | 一种用于体内软骨修复的转化生长因子复合支架的制备方法及其应用 | |
CN104587531B (zh) | 一种修复关节软骨损伤的凝胶支架的制备方法 | |
Zhang et al. | Injectable conductive micro-cryogel as a muscle stem cell carrier improves myogenic proliferation, differentiation and in situ skeletal muscle regeneration | |
CN106397795A (zh) | 一种混合透明质酸凝胶及其制备方法 | |
CN108670946A (zh) | 治疗关节软骨损伤的细胞凝胶制剂及其用途和所用的保持冻存细胞活性的凝胶溶液 | |
Zhang et al. | Repair of osteochondral defect using icariin-conditioned serum combined with chitosan in rabbit knees | |
Sun et al. | Advances in the treatment of partial-thickness cartilage defect | |
CN101690830B (zh) | 组织工程用仿生软骨细胞外基质的制备方法 | |
JP6456826B2 (ja) | 線維芽細胞からのエクスビボ軟骨生成 | |
CN107693844A (zh) | 一种组合物凝胶与应用 | |
CN106075574A (zh) | 一种修复关节软骨损伤的凝胶支架的制备方法 | |
CN105107018B (zh) | 一种无菌可注射材料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161109 |